

# Marc sorigue

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2675955/publications.pdf>

Version: 2024-02-01

108  
papers

499  
citations

840119

11  
h-index

940134

16  
g-index

111  
all docs

111  
docs citations

111  
times ranked

715  
citing authors

#	ARTICLE	IF	CITATIONS
1	New biological insights into atypical chronic lymphocytic leukemia. International Journal of Laboratory Hematology, 2022, 44, .	0.7	0
2	Monocyte subset distribution in myeloproliferative and myelodysplastic/myeloproliferative neoplasms with monocytosis. Leukemia Research, 2022, 112, 106771.	0.4	1
3	Overlap between CD23 and CD200 in leukemic lymphoproliferative disorders. International Journal of Laboratory Hematology, 2022, 44, .	0.7	1
4	Monocyte subset analysis in the presence of paroxysmal nocturnal hemoglobinuria. A case report. International Journal of Laboratory Hematology, 2022, 44, 980-982.	0.7	0
5	CD34+CD19 <sup>+</sup> CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. Blood, 2022, 140, 38-44.	0.6	20
6	Mortality among patients with low-grade follicular lymphoma: A binational retrospective analysis. Cancer, 2022, , .	2.0	3
7	Flow cytometry in leukaemic B cell lymphoproliferative disorders. New scores, same old concerns. International Journal of Laboratory Hematology, 2022, 44, .	0.7	0
8	Contribution of anti-CT cell receptor beta constant 1 to the classification of a mediastinal mass. Cytometry Part B - Clinical Cytometry, 2021, 100, 689-691.	0.7	1
9	Systematic review of staging bone marrow involvement in B cell lymphoma by flow cytometry. Blood Reviews, 2021, 47, 100778.	2.8	8
10	The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients. European Journal of Haematology, 2021, 106, 428-432.	1.1	1
11	CD43 in the malignant flow cytometry laboratory in 2020. Expert Review of Hematology, 2021, 14, 123-136.	1.0	4
12	Chronic myelomonocytic leukemia and blastic plasmacytoid dendritic cell neoplasm. A case report and systematic review. Cytometry Part B - Clinical Cytometry, 2021, 100, 292-295.	0.7	5
13	R <sup>2</sup> COMP versus R <sup>2</sup> CHOP as first-line therapy for diffuse large B-cell lymphoma in patients $\geq 60$ years: Results of a randomized phase 2 study from the Spanish GELTAMO group. Cancer Medicine, 2021, 10, 1314-1326.	1.3	13
14	Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months. Leukemia and Lymphoma, 2021, 62, 1639-1647.	0.6	4
15	Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma. Journal of Thrombosis and Thrombolysis, 2021, 52, 848-853.	1.0	2
16	Concordance between flow cytometry CLL scores. International Journal of Laboratory Hematology, 2021, 43, 743-751.	0.7	4
17	Flow cytometric expression of CD71, CD81, CD44 and CD39 in B cell lymphoma. Scandinavian Journal of Clinical and Laboratory Investigation, 2021, 81, 413-417.	0.6	3
18	The lymphocyte-to-monocyte ratio in follicular lymphoma. Leukemia and Lymphoma, 2021, 62, 1-4.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Actualización en el diagnóstico, pronóstico y tratamiento del linfoma folicular. Medicina Clínica, 2021, 157, 440-448.	0.3	4
20	Robustness and pragmatism of the evidence supporting the European Society for Medical Oncology guidelines for the diagnosis, treatment, and follow-up of follicular lymphoma. Expert Review of Hematology, 2021, 14, 655-668.	1.0	1
21	Divergent leukaemia subclones as cellular models for testing vulnerabilities associated with gains in chromosomes 7, 8 or 18. Scientific Reports, 2021, 11, 21145.	1.6	0
22	Follicular lymphoma: An update on diagnosis, prognosis, and management. Medicina Clínica (English) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.1	2
23	Positive predictive value of CD200 positivity in the differential diagnosis of chronic lymphocytic leukemia. Cytometry Part B - Clinical Cytometry, 2020, 98, 441-448.	0.7	16
24	Immune Infiltration and the Potential for a Biology-Guided Approach to Follicular Lymphoma. Journal of Clinical Oncology, 2020, 38, 647-648.	0.8	1
25	Flow Cytometry in the Differential Diagnosis of CD10-Positive Nodal Lymphomas. Laboratory Medicine, 2020, 51, 385-393.	0.8	3
26	Long-term outcome comparing histological grades of follicular lymphoma patients treated with immunochemotherapy as first-line therapy: A retrospective analysis from two institutions. European Journal of Haematology, 2020, 104, 198-206.	1.1	3
27	Precision medicine in follicular lymphoma: Focus on predictive biomarkers. Hematological Oncology, 2020, 38, 625-639.	0.8	4
28	Polycythemia Vera Evolution to Chronic Myelomocytic Leukemia: The Prognostic Value of Next Generation Sequencing. HemaSphere, 2020, 4, e466.	1.2	4
29	Diagnostic performance of the ClearLab 10C B cell tube. Cytometry Part B - Clinical Cytometry, 2020, 100, 519-530.	0.7	6
30	Results of R-ESHAP as salvage therapy in refractory/relapsed follicular lymphoma: a real-world experience on behalf of GELCAB group. Annals of Hematology, 2020, 99, 1627-1634.	0.8	5
31	Brief communication: Distribution of bone marrow cell subsets and hemodilution in patients with acute leukemia. International Journal of Laboratory Hematology, 2020, 42, e192-e195.	0.7	6
32	41BB-based and CD28-based CD123-redirectioned T-cells ablate human normal hematopoiesis in vivo. , 2020, 8, e000845.		37
33	FMOD expression in whole blood aids in distinguishing between chronic lymphocytic leukemia and other leukemic lymphoproliferative disorders. A pilot study. Cytometry Part B - Clinical Cytometry, 2020, 98, 421-428.	0.7	9
34	Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia. Annals of Hematology, 2020, 99, 1135-1136.	0.8	1
35	Recent developments and persisting challenges in the prevention and treatment of venous thromboembolism in patients with hematological malignancies. Leukemia and Lymphoma, 2020, 61, 1277-1291.	0.6	7
36	Clinical impact of high platelet count and high hematocrit. Journal of Thrombosis and Haemostasis, 2020, 18, 521-522.	1.9	0

#	ARTICLE	IF	CITATIONS
37	Oral anticoagulation in patients with active cancer and atrial fibrillation: current challenges. Polish Archives of Internal Medicine, 2020, 130, 878-886.	0.3	0
38	Incidence of solid cancer in patients with follicular lymphoma. Acta Oncológica, 2019, 58, 1564-1569.	0.8	5
39	Use of anticoagulation in patients with breast cancer and atrial fibrillation. Breast, 2019, 48, 98.	0.9	1
40	Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era. British Journal of Haematology, 2019, 187, 364-371.	1.2	11
41	<scp>m7FLIPI</scp> and targeted sequencing in high-risk follicular lymphoma. Hematological Oncology, 2019, 37, 564-568.	0.8	2
42	Assessing the Effect of the BRIDGE Trial in Clinical Practice. American Journal of Medicine, 2019, 132, e630.	0.6	0
43	Platelet satellitism around lymphocytes: Case report and literature review. International Journal of Laboratory Hematology, 2019, 41, e81-e83.	0.7	5
44	Flow Cytometry in Double and Triple Hit Lymphomas. Cytometry Part B - Clinical Cytometry, 2019, 96, 319-320.	0.7	1
45	Is Longer Progression-Free Survival a Goal Worth Pursuing in Follicular Lymphoma?. Journal of Clinical Oncology, 2019, 37, 758-758.	0.8	2
46	Interactions between direct anticoagulants and chemotherapy. Annals of Oncology, 2019, 30, 1170.	0.6	1
47	Evidence for resumption of anticoagulation after a previous major gastrointestinal bleeding. Thrombosis Research, 2019, 178, 99-100.	0.8	0
48	On cancer and atrial fibrillation: Nuances and limitations. European Journal of Internal Medicine, 2019, 62, e22-e23.	1.0	1
49	Recent landmark studies in follicular lymphoma. Blood Reviews, 2019, 35, 68-80.	2.8	9
50	Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma. Leukemia and Lymphoma, 2019, 60, 2524-2531.	0.6	4
51	Further Examining the TROG 99.03 Trial in Early-Stage Follicular Lymphoma: Cure Rate and the Role of Positron Emission Tomography. Journal of Clinical Oncology, 2019, 37, 256-257.	0.8	2
52	Anticoagulation for atrial fibrillation in patients with active cancer. International Journal of Cardiology, 2019, 280, 98.	0.8	1
53	Dabigatran for catastrophic antiphospholipid syndrome. Blood Coagulation and Fibrinolysis, 2019, 30, 364-365.	0.5	2
54	Atrial Fibrillation and Stroke Risk in Patients With Cancer: A Primer for Oncologists. Journal of Oncology Practice, 2019, 15, 641-650.	2.5	25

#	ARTICLE	IF	CITATIONS
55	Refining the Limits of Borderline Lymphoproliferative Disorders. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 351-358.	0.7	13
56	Thromboembolism and bleeding in patients with cancer and mechanical heart valves. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 454-461.	1.0	1
57	Overall survival in patients with relapsed/refractory high grade B-cell lymphomas treated with gemcitabine, oxaliplatin with or without rituximab. <i>Leukemia and Lymphoma</i> , 2019, 60, 3324-3326.	0.6	1
58	Atypical chronic lymphocytic leukemia: Brief historical overview and current usage of an equivocal concept. <i>International Journal of Laboratory Hematology</i> , 2019, 41, e17-e19.	0.7	7
59	Starting anticoagulation with vitamin k antagonists alone or with concomitant low-molecular weight heparin for non-valvular atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2019, 59, e14-e15.	1.0	0
60	Risk of Cardioembolic Stroke in Patients With Cancer and Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2018, 121, 1656-1657.	0.7	4
61	Anticoagulant Agents for Atrial Fibrillation in Cancer Patients. <i>American Journal of Cardiology</i> , 2018, 121, 1011-1012.	0.7	0
62	Usefulness of the CLLflow score. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 950-952.	0.7	8
63	Consistency of the Moreau <sc>CLL</sc> score. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, e22376.	0.9	4
64	Arterial Thromboembolism in Non-Hodgkin Lymphoma. <i>Journal of the American College of Cardiology</i> , 2018, 71, 258-259.	1.2	0
65	Recomendaciones del Grupo Catal�n de Trombosis (Tromboc@t Working Group) para el tratamiento de los pacientes que reciben anticoagulantes orales directos. <i>Medicina Cl�nica</i> , 2018, 151, 210.e1-210.e13.	0.3	2
66	Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review. <i>Leukemia and Lymphoma</i> , 2018, 59, 2602-2611.	0.6	1
67	Expression of CD43 in chronic lymphoproliferative leukemias. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 136-142.	0.7	30
68	Phenotypic Characterization of Trisomy 12 Monoclonal <sc>B</sc>-Cell Lymphocytosis. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 374-378.	0.7	5
69	Triple therapy with dual antiplatelet treatment and direct oral anticoagulants. <i>European Journal of Internal Medicine</i> , 2018, 47, e20.	1.0	0
70	La revisi�n de 2016 de la clasificaci�n de la OMS de las neoplasias linfoides: la visi�n del cl�nico. <i>Medicina Cl�nica</i> , 2018, 150, 64-66.	0.3	3
71	Current prognostic and predictive factors in follicular lymphoma. <i>Annals of Hematology</i> , 2018, 97, 209-227.	0.8	22
72	Adoption of Bio/Data Collagen for the assessment of platelet function with the Multiplate� Analyzer. <i>Thrombosis Research</i> , 2018, 161, 33-35.	0.8	4

#	ARTICLE	IF	CITATIONS
73	Is there a role for the international prognostic index in follicular lymphoma?. <i>Annals of Hematology</i> , 2018, 97, 713-715.	0.8	3
74	Reply to Foley et Al., "Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation?" <i>Cancer Genetics</i> , 2018, 220, 77.	0.2	0
75	Difference in <scp>CD</scp>5 and <scp>CD</scp>10 expression according to anatomic site. <i>International Journal of Laboratory Hematology</i> , 2018, 40, e4-e7.	0.7	2
76	The case for lymphoma-specific survival. <i>Expert Review of Hematology</i> , 2018, 11, 263-264.	1.0	0
77	Importance of dosing direct oral anticoagulants appropriately. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 465-466.	0.1	0
78	Indications and use of, and incidence of major bleeding with, antithrombotic agents in myelodysplastic syndrome. <i>Leukemia Research</i> , 2018, 73, 24-28.	0.4	2
79	Predictive gene-expression score for follicular lymphoma. <i>Lancet Oncology</i> , The, 2018, 19, e279.	5.1	0
80	Treatment of localized "stage follicular lymphoma. <i>European Journal of Haematology</i> , 2018, 101, 245-256.	1.1	6
81	Routine surveillance imaging in follicular lymphoma. <i>Annals of Hematology</i> , 2018, 97, 2263-2264.	0.8	4
82	Incidence, predictive factors, management, and survival impact of atrial fibrillation in non-Hodgkin lymphoma. <i>Annals of Hematology</i> , 2018, 97, 1633-1640.	0.8	9
83	Importancia de la dosis de anticoagulantes orales directos. <i>Medicina Clínica</i> , 2018, 151, 465-466.	0.3	0
84	The persistent uncertainty of when to recommend allogeneic stem cell transplantation in follicular lymphoma. <i>Cancer</i> , 2018, 124, 3454-3455.	2.0	0
85	Hemorragia intracraneal durante el tratamiento con apixab "n. <i>Medicina Clínica</i> , 2017, 148, 47-48.	0.3	1
86	Pron "stico similar de los linfomas transformados y los linfomas difusos de c "lulas B grandes de novo en pacientes tratados con inmunoterapia. <i>Medicina Clínica</i> , 2017, 148, 243-249.	0.3	1
87	Applicability of the results of thrombophilia studies in clinical practice. <i>European Journal of Internal Medicine</i> , 2017, 39, e27-e28.	1.0	1
88	Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome. <i>Hematological Oncology</i> , 2017, 35, 520-527.	0.8	20
89	Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma. <i>Leukemia Research</i> , 2017, 58, 98-101.	0.4	3
90	Retinal vein occlusion and paroxysmal nocturnal hemoglobinuria. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 63-66.	1.0	2

#	ARTICLE	IF	CITATIONS
91	HIV-infection has no prognostic impact on advanced-stage Hodgkin lymphoma. <i>Aids</i> , 2017, 31, 1445-1449.	1.0	14
92	Intracranial hemorrhage during apixaban treatment. <i>Medicina Clínica (English Edition)</i> , 2017, 148, 47-48.	0.1	0
93	Late isolated intraocular relapse of a systemic diffuse large B-cell lymphoma detected by flow cytometry. <i>Annals of Hematology</i> , 2017, 96, 523-524.	0.8	0
94	Number needed to treat for direct oral anticoagulants over warfarin in atrial fibrillation. <i>Medicina Clínica (English Edition)</i> , 2017, 149, 275-276.	0.1	0
95	Número de pacientes necesario a tratar con anticoagulantes orales directos con respecto a warfarina en la fibrilación auricular. <i>Medicina Clínica</i> , 2017, 149, 275-276.	0.3	0
96	Relapse risk after autologous stem cell transplantation in patients with lymphoma based on CD34+ cell dose. <i>Leukemia and Lymphoma</i> , 2017, 58, 916-922.	0.6	5
97	Open questions in watchful waiting for follicular lymphoma. <i>British Journal of Haematology</i> , 2017, 179, 679-681.	1.2	4
98	Clinicobiological features, treatment and survival of 457 patients with histological Grades 3A and 2 follicular lymphoma mostly treated with immunochemotherapy. <i>British Journal of Haematology</i> , 2016, 172, 470-473.	1.2	14
99	The clinical dilemma of grade 3 follicular lymphoma. <i>Annals of Oncology</i> , 2016, 27, 1974.	0.6	5
100	New drugs for follicular lymphoma. <i>Leukemia Research</i> , 2016, 49, 38-46.	0.4	3
101	Highly variable mutational profile of <i>ASXL1</i> in myelofibrosis. <i>European Journal of Haematology</i> , 2016, 97, 331-335.	1.1	6
102	The role of T-cell phenotype and T-cell receptor rearrangement in the diagnosis of T-cell malignancies. <i>Leukemia and Lymphoma</i> , 2016, 57, 244-246.	0.6	4
103	The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment. <i>Leukemia Research</i> , 2015, 39, 853-858.	0.4	15
104	Flow cytometry for detection of central nervous system disease in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2190-2192.	0.6	5
105	CD200 in High-Grade Lymphoma, Chronic Lymphocytic Leukemia, and Chronic Lymphocytic Leukemia Phenotype Monoclonal B-Cell Lymphocytosis. <i>American Journal of Clinical Pathology</i> , 2015, 144, 677-679.	0.4	8
106	A case of CD138 <sup>+</sup> /CD19 <sup>+</sup> /CD4 <sup>+</sup> IgD plasma cell leukemia. , 2015, 88, 69-73.		2
107	Prevalence, Predictive Factors Therapy and Outcome of Patients with Follicular Lymphoma Refractory to First Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 1510-1510.	0.6	2
108	Advanced Stage Hodgkin's Lymphoma Has More Aggressive Characteristics but Similar Outcome in HIV-Infected Than in HIV-Negative Patients in the Combination Antiretroviral Therapy Era. <i>Blood</i> , 2014, 124, 4435-4435.	0.6	0